Benjamin P. Levy, MD

Benjamin P. Levy, MD, is clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and associate professor of oncology at Johns Hopkins University School of Medicine.

Articles

Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy

July 12th 2022

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Molecular Testing in Advanced-Stage NSCLC: Use of Liquid Biopsy

July 5th 2022

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

Use of Molecular Profiling in Early-Stage Non–Small Cell Lung Cancer

July 5th 2022

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.

Real-World Data and Barriers to Use of Molecular Testing in NSCLC

June 28th 2022

A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.

Optimal Molecular Testing Practices in Non–Small Cell Lung Cancer

June 28th 2022

Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.

Dr. Levy on Potential Methods to Optimize Molecular Testing in Lung Cancer

February 7th 2022

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

Dr. Levy on Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC

September 20th 2021

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer.

Dr. Levy on the Mechanism of Action of Telaglenastat in NSCLC

October 28th 2020

Benjamin P. Levy, MD, discusses the mechanism of action of telaglenastat in non–small cell lung cancer.

Dr. Levy on the Role of Dabrafenib/Trametinib in BRAF V600E-Mutant NSCLC

September 28th 2020

Benjamin P. Levy, MD, discusses the role of the combination of dabrafenib and trametinib in BRAF V600E-mutant non–small cell lung cancer.

Dr. Levy on the DFS Benefit Achieved With Adjuvant Osimertinib in EGFR+ NSCLC

September 25th 2020

Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

July 24th 2020

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.

Dr. Levy on Emerging Biomarkers and Corresponding Therapies in Lung Cancer

April 4th 2020

Benjamin P. Levy, MD, discusses emerging biomarkers and their respective therapies in lung cancer.

Dr. Levy on the Current State of Liquid Biopsies Across Tumor Types

February 22nd 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

Dr. Levy on Repeat Testing in NSCLC

February 20th 2020

Benjamin P. Levy, MD, discusses the importance of repeat testing in non–small cell lung cancer.

Dr. Levy on Ongoing Research Evaluating the Use of Liquid Biopsies in Lung Cancer

February 8th 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses ongoing research regarding the use of liquid biopsies in lung cancer.

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer

January 24th 2020

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Dr. Levy on Treatments for Oncogenic-Driven NSCLC

December 21st 2019

Benjamin P. Levy, MD, discusses treatment options for patients with oncogenic-driven non–small cell lung cancer.

Dr. Levy on First-Line Treatment for Nondriver NSCLC

November 28th 2019

Benjamin P. Levy, MD, discusses first-line treatment for patients with nondriver non–small cell lung cancer.

Dr. Levy on Molecular Drivers in NSCLC

November 15th 2019

Benjamin P. Levy, MD, discusses the identification of molecular drivers in non–small cell lung cancer.

Dr. Levy Discusses the Outlook for Oncogene-Driven NSCLC

May 30th 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the outlook for patients with oncogene-driven non–small cell lung cancer.